Drugs / TanCAR7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03097770 | Apr 2017 → May 2019 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma +1 | Chinese PLA General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TanCAR7 | “In this single-arm, single-center, registrational phase 2 trial, tandem CD19/CD20 chimeric antigen receptor (CAR) T cell (TanCAR7) therapy showed promising efficacy and safety...” PMID 41804087 ↗ Mar 2026 |
| Action | Deplete | “Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to...” NCT03097770 ↗ |
| Modality | Cell therapy | “tandem CD19/CD20 chimeric antigen receptor (CAR) T cell (TanCAR7) therapy” PMID 41804087 ↗ Mar 2026 |